File not found

Minneapolis Venture Studio Invenshure Launches New Biotech Company

A new biotech company has just hit the scene courtesy of Minneapolis-based venture studio Invenshure

Focused on precision oncology, MEKanistic Therapeutics is spearheaded by Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA. The two are specialists in the MEK inhibitor field, a type of chemical or drug that block mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2. The drugs have been shown to be effective in fighting some cancers. MEKanistic's drug blocks two pathways used to signal cancer growth in particular, EGFR and PI3K.

"MTX-531's initial application targets head and neck cancers with 900,000 cases worldwide per year,"  Chief Scientific Officer, Dr. Sebolt-Leopold said in a release. "Ultimately, this drug has possible future applications for colon/rectal, esophageal, pancreatic, and some breast cancers. Our work could potentially impact millions of people each year."

Alex Skjong
Alex oversees the content produced for BETA, Twin Cities Startup Week, and When he’s not writing or editing, there’s a good chance he’s enjoying a refreshing brew and explaining the merits of heavy metal (of which there are many).